Advertised drug | Indication | Comparison | Reviewed evidence | Evidence categorisation |
---|---|---|---|---|
Drug groups | ||||
1. Beta2-agonist + steroid inhalations | 1. Asthma | 1. Steroid inhalation only | Uncertain benefits | |
- | 2. COPD | 2. Beta2-agnoist inhalation only | Systematic review [31] | Uncertain benefits |
2. Beta2-agonist + anticholinergic agents | 2. COPD | 3. Beta2-agonist only | Systematic review [32] | Uncertain benefits |
- | 2. COPD | 4. Anticholinergic agent only | Systematic review [32] | Uncertain benefits |
3. ADHD medications | ||||
Lisdexamfetamine | 3. ADHD | 5. Methylphenidate | No evidence source | No evidence |
Atomoxetine | 3. ADHD | 6. Methylphenidate | One clinical trial [33]a | No added benefits |
4. New oral anticoagulations | ||||
Rivaroxaban | 4. Atrial fibrillation | 7. Warfarin | FDA report [34] | No added benefits |
Dabigatran | 4. Atrial fibrillation | 8. Warfarin | FDA report [35] | No added benefits |
Single drugs | ||||
5. Paracetamol modified-release | 5. Pain | 9. Regular paracetamol | No evidence source | No evidence |
6. Vortioxetine | 6. Depression | 10. Duloxetine | Systematic review [36]a | No added benefits |
7. Aripiprazole intramuscular depot | 7. Schizophrenia | 11. Aripiprazole oral tablet | EMA report [37] | Uncertain benefits |
8. Pneumococcal vaccine | 8. Pneumococcal pneumonia | 12. Placebo | Uncertain benefits | |
9. Canagliflozin | 9. Diabetes mellitus type 2 (single therapy) | 13. Glimeride | IQWiG report [40] | No evidence |
- | 10. Diabetes mellitus type 2 (add-on to metformin) | 14. Glimerpiride add-on to metformin | IQWiG report [40] | Uncertain evidence |